PGE2(Prostaglandin E2) ELISA Kit Basic Information

Feiyue's PGE2(Prostaglandin E2) ELISA Kit 
is an ELISA reagent for detection of PGE2(Prostaglandin E2) in serum, plasma or cell with sensitivity, specificity and consistency.

PGE2(Prostaglandin E2) Introduction

Prostaglandin E2 (PGE2), also known as dinoprostone, is a naturally occurring prostaglandin with oxytocic properties that is used as a medication. Dinoprostone is used in labor induction, bleeding after delivery, termination of pregnancy, and in newborn babies to keep the ductus arteriosus open. In babies it is used in those with congenital heart defects until surgery can be carried out. It is also used to manage gestational trophoblastic disease. It may be used within the vagina or by injection into a vein.

The aerosol form of PGE2 serves as a bronchodilator, but its use in this setting is limited by the fact that it also causes coughing. PGE2, similarly to PGE1, acts as a direct vasodilator by acting on smooth muscle to cause dilation of blood vessels. In addition, PGE2 inhibits platelet aggregation. PGE2 also suppresses T cell receptor signaling and proliferation, and may play a role in resolution of inflammation. In addition, PGE2 limits the immune response by preventing B-lymphocyte differentiation and their ability to present antigens.

PGE2(Prostaglandin E2) ELISA Kit Test method

This kit was based on Competitive-ELISA detection method. The microtiter plate provided in this kit has been pre-coated with target. During the reaction, target in the sample or standard competes with a fixed amount of target on the solid phase supporter for sites on the Biotinylated Detection Antibody specific to target. Excess conjugate and unbound sample or standard are washed from the plate, and HRP-Streptavidin (SABC) is added to each microplate well and incubated. Then TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm. The concentration of target in the samples is then determined by comparing the OD of the samples to the standard curve.

Reference:

1, "Dinoprostone". The American Society of Health-System Pharmacists. Archived from the original on 16 January 2017. Retrieved 8 January 2017.

2, Shirley M (October 2018). "Dinoprostone Vaginal Insert: A Review in Cervical Ripening". Drugs. 78 (15): 1615–1624. doi:10.1007/s40265-018-0995-2. PMID 30317521. S2CID 52978808.